

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

INSIDE INFORMATION ANNOUNCEMENT
PROPOSED IMPLEMENTATION OF THE H SHARE FULL
CIRCULATION BY THE COMPANY

This announcement is made by TransThera Sciences (Nanjing), Inc. (藥捷安康(南京)科技股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Guidelines on Application for “Full Circulation” of Domestic Unlisted Shares of H-share Companies (《H股公司境內未上市股份申請“全流通”業務指引》) issued by the China Securities Regulatory Commission (the “**CSRC**”) on November 14, 2019 and further amended on August 10, 2023 (the “**Guidelines**”) regarding the procedures of application by companies whose H shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

In view of the Guidelines, the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company considered and approved the submission of an application to the CSRC in respect of the conversion of 44,971,128 domestic shares of the Company (“**Domestic Shares**”) held by 10 shareholders of the Company into H shares of the Company (“**H Shares**”) (representing approximately 11.33% of the total issued shares of the Company as at the date of this announcement) on October 20, 2025. Upon obtaining all the relevant approvals (including the approvals from the CSRC and the Stock Exchange) and having complied with all the applicable laws, regulations and rules, such Domestic Shares will be converted into H Shares and be eligible to be listed and traded on the Main Board of the Stock Exchange (the “**Conversion and Listing**”). Pursuant to the articles of association of the Company, no further shareholders’ meeting is required to be convened to approve the Conversion and Listing.

As of the date of this announcement, the details of the Company’s implementation plan of the Conversion and Listing have not been finalised and the final number of Domestic Shares to be converted as well as the completion of the Conversion and Listing are subject to the performance of relevant procedures as required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. The Company will make further announcements on the progress of the Conversion and Listing in compliance with the Listing Rules as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, October 20, 2025

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.